BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Events//NONSGML v1.0//EN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTART;TZID="Pacific Time (US & Canada)":20201019T161000
DTEND;TZID="Pacific Time (US & Canada)":20201019T170000
SUMMARY:CHE 598 Seminar: Engineering Viruses for Therapeutic Use
LOCATION:Online
DESCRIPTION:Presenter: Ching-An Peng, Chair & Professor, Department of Chemical & Biological Engineering, University of Idaho\n\nAlthough several trials showed significant shrinkage when viruses were injected directly into tumor nodules, systemic intravenous delivery of virotherapeutics is required for the treatment of metastatic cancers. This presents a challenge, because viruses could be rapidly cleared from the blood circulation via the host immune system before they reach tumor sites. To be effective, therapeutic viruses for intravenous delivery need to possess adequate stability in blood to selectively target cancer cells and elicit tumor oncolysis. In this study, we harnessed CD47’s antiphagocytic and CD200’s anti-inflammatory characteristics to functionalize viruses and then loaded onto macrophages to explore the potential use of such biomimetic viruses for gene delivery. Our results showed that nano-sized viral particles decorated with CD47-CD200 fusion protein decreased phagocytosis activities of macrophages. Such diminution of phagocytosis was examined to be associated with (1) CD47-SIRPα interaction and (2) downregulation of Toll-like receptor 4 expression on the surface of macrophages. Moreover, J774A.1 macrophages treated with CD47-CD200-tethered viruses decreased the secretion of pro-inflammatory cytokines.
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:REMINDER
TRIGGER;RELATED=START:-PT00H15M00S
END:VALARM
END:VEVENT
END:VCALENDAR